HGH denotes human growth hormone. Clinical research on recombinant growth hormone formulations, including somatropin, provides endocrine context but does not validate the identity, potency or clinical suitability of a research vial.
HGH is the supplied human growth hormone identity. Listed IU values are catalogue specifications, not independent verification of biological potency or equivalence to a clinical somatropin product.
Laboratory research only
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
Human growth hormone research includes controlled studies in people with diagnosed growth hormone deficiency. The linked multicentre trial examined body composition, circulating IGF-I, blood lipids and functional outcomes in adults with adult-onset deficiency. Its results concern a defined patient population receiving a specified clinical preparation under study monitoring. Findings from clinical recombinant growth hormone formulations, such as somatropin, cannot establish equivalence with a separate research-labelled vial. Product identity, biological potency and formulation require their own documentation. The literature is included to describe endocrine research questions, without implying a general performance, body-composition or anti-ageing effect for this listing.
Research context
Adult growth hormone deficiency
Body composition and lipid measurements
Strength, endurance and quality-of-life outcomes
Batch specification
HGH is the supplied human growth hormone identity. Listed IU values are catalogue specifications, not independent verification of biological potency or equivalence to a clinical somatropin product.
EXPLORE THE EVIDENCE
Studies & research references
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
A multicentre, placebo-controlled study in 166 adults with growth hormone deficiency assessed body composition, lipids and function. Findings were mixed across endpoints and apply to the clinical preparation and population studied.
HGH is currently listed in 10 IU, 12 IU, 15 IU, 24 IU, 36 IU. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
Is a COA available for HGH?
No laboratory report is currently published for this compound. Request the available documentation before relying on any batch-specific measurement. A scientific paper is not a substitute for a COA.
A catalogue listing is not a laboratory measurement. Check original documentation for the selected strength and batch before relying on identity, purity or quantity information.
Tesamorelin is a growth hormone-releasing hormone analogue studied in defined clinical populations, particularly people with HIV-associated abdominal fat accumulation. Published findings concern the study formulations and do not establish the properties of this research vial.
Ipamorelin is a synthetic peptide studied as a growth hormone secretagogue and ghrelin-receptor agonist. Its literature includes animal pharmacology and a human trial of postoperative bowel function, with distinct endpoints and limitations.
This listing is CJC-1295 No DAC. The linked human study concerns the related, long-acting albumin-binding CJC-1295 compound and is provided as context, not direct evidence for the no-DAC material.